Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Nd:YAG laser, Diode laser.
- Who it may be relevant to
- Registry conditions: Nd:YAG Laser, Sclerotherapy, Diode Laser, Reticular Veins. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparative Study Between Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
Overview
This study aims to compare the efficacy (in terms of vein clearance) and safety of Nd:YAG laser combined with injection sclerotherapy versus diode laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias using the Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique.
Detailed description
Reticular veins and telangiectasias (spider veins) represent common chronic venous disorders affecting a large proportion of the adult population, particularly women.
The Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique has emerged as an innovative method combining transdermal laser therapy, injection sclerotherapy, and skin cooling. This multimodal approach enhances visualization of feeder veins using augmented reality or vein illumination systems, allowing precise targeting and improved clearance rates. Cooling reduces pain and protects the epidermis, making the procedure more tolerable and safer.
Nd:YAG laser (1064 nm) is considered the cornerstone of the CLaCS technique due to its deeper penetration and selective photothermolysis of hemoglobin. It effectively targets deeper reticular veins (up to 3-4 mm depth), induces vessel wall contraction, and facilitates subsequent sclerotherapy.
Interventions
- Device Nd:YAG laser
Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS). - Drug Diode laser
Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS).
Primary outcome measures
- Degree of vein clearance [Time frame: 6 months postoperatively]
Secondary outcome measures (5)
- Degree of pain [Time frame: 6 months postoperatively]
- Degree of patient satisfaction [Time frame: 6 months postoperatively]
- Incidence of complications [Time frame: 6 months postoperatively]
- Number of treatment sessions required [Time frame: 6 months postoperatively]
- Recurrence rate [Time frame: 6 months postoperatively]
Eligibility criteria
Inclusion criteria
- Patients aged 18-60 years.
- Both sexes.
- Presence of reticular veins and/or telangiectasias (CEAP classification C1).
- Fitzpatrick skin types II-V.
- Patients seeking cosmetic treatment.
Exclusion criteria
- Pregnancy or lactation.
- History of deep vein thrombosis.
- Coagulation disorders.
- Allergy to sclerosant agents.
- Active skin infection at treatment site.
- Previous treatment of target veins within 6 months.
- Great saphenous vein or short saphenous vein incompetence.
- Deep venous insufficiency or thrombosis.
- Abnormal venous duplex findings.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Ain Shams University — Cairo
Identifiers
NCT: NCT07678697 · IRB 00006379 (17/05/2026)